Léčivé přípravky s obsahem účinné látky PANITUMUMAB
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| S2025/00922/00 | 08. 01. 2026 | Amgen s.r.o. | 15 985 651,11 | 14 272 902,78 | 15 985 651,11 | 14 272 902,78 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| S2025/00922/00 | S2025_00922_00 Kupní smlouva PANITUMUMAB_anonym.pdf | Smlouva | 12. 01. 2026 12:08 | Dokument není zavirovaný |
List of Participants
| Show detail | |||||||
|---|---|---|---|---|---|---|---|
| Amgen s.r.o. | Praha | 15 985 651,11 | 14 272 902,78 | CZK | Yes | Yes |
Written Report - Justification
| Show detail | Justification for using other means of communication for submitting bids instead of electronic means | Justification for not dividing an above-threshold public procurement into lots | Justification for setting requirements for proving turnover in case of proceeding according to Article 78(3), if not stated in the tender documentation |
|---|---|---|---|
| Předmět veřejné zakázky není pro rozdělení vhodný. | Požadavek na prokázání obratu nebyl stanoven. |